Search for Mylan NV. Find the share by name or ticker symbol: MYL. Research its history to confirm it's a solid investment against your financial goals. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mylan NV reaches your desired price.
Full Answer
How does Mylan NV's price/earnings ratio compare to its peers?
Mar 31, 2021 · However, analysts commonly use some key metrics to help gauge the value of a stock. Mylan NV's P/E ratio. Mylan NV's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Mylan NV shares trade at around 31x recent earnings.
Who buys Mylan stock?
How to buy shares in Viatris. Compare share trading platforms. Use our comparison table to help you find a platform that fits you. Open your brokerage account. Complete an application with your details. Confirm your payment details. Fund your account. …
Where can you buy MYL shares?
Jun 17, 2020 · How to buy shares in Mylan NV Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees. Open and fund your brokerage account.
Is Mylan’s PE ratio too expensive?
Cut your losses sooner, stick with your winners longer. Mylan NV (MYL) $15.94 +0.09 (+0.58%) How much to buy? Powered by. Risk State. Performance.
How can I buy Viatris stock?
Invest in Viatris Inc on Stash , you can buy Viatris Inc stock in any dollar amount, or any other fund or stock you know on Stash.
Is Mylan a good stock to buy?
Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. Mylan (MYL) is a stock many investors are watching right now. MYL is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 4.92.27 Jan 2020
What happened to my MYL shares?
MYL shares have been suspended from trade since February, but Mr Lamb said the ASX would not let MYL return to quotation until it bought a new project.15 Sept 2021
How do you purchase a publicly traded stock?
To buy stocks, you'll typically need the assistance of a stockbroker, since you cannot simply call up a stock exchange and ask to buy stocks directly. When you use a stockbroker, whether a human being or an online platform, you can choose the investment that you wish to buy or sell and how the trade should be handled.
Will Mylan stock go up?
Earnings for Mylan are expected to grow by 0.90% in the coming year, from $4.46 to $4.50 per share.
Does Pfizer own Mylan?
Now that the FTC has formally cleared the merger, the new firm, Viatris, will become a generics giant, with Pfizer owning 57% and Mylan owning 43%.4 Nov 2020
How do beginners buy stocks?
The easiest way to buy stocks is through an online stockbroker. After opening and funding your account, you can buy stocks through the broker's website in a matter of minutes. Other options include using a full-service stockbroker, or buying stock directly from the company.
Can I buy 1 share of Amazon?
On Wednesday, the company said that its board had approved a 20-for-1 stock split. The move means if you already own Amazon stock, you'll receive 20 shares for each single share you own, and if you don't own Amazon stock, you'll be able to buy it at a much lower price.10 Mar 2022
How do I buy stocks online without a broker?
It is possible to buy stock without a broker. In fact, there are three alternatives to using a full-service broker: opening an online brokerage account, investing in a dividend reinvestment plan, and investing in a direct stock purchase plan.
What is Mylan N. V.?
, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally . It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.
How to calculate Viatris's P/E ratio?
Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
What is Mylan N.V.?
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
What is the EBITDA of Mylan?
Mylan NV's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.5 billion (£2.6 billion). The EBITDA is a measure of a Mylan NV's overall financial performance and is widely used to measure a its profitability.
What is Mylan's social score?
Mylan NV's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan NV is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
What is the environmental score of Mylan?
Mylan NV's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan NV is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Is Mylan NV a leader?
That could suggest that Mylan NV is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Latest Stock & ETF Risk Analysis
Protect your Investments with instant risk alerts and portfolio monitoring – and grow your money Smart (R).
How SmartStops Helps You Profit
Receive our email and mobile Instant Risk Alerts, letting you know in real-time when your stocks or ETFs need attention.
About Mylan N.V
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Mylan Treats A Wide Variety Of Diseases
Mylan was founded in 1961, and it has subsidiaries around the world, including in the U.S., Canada, Brazil, New Zealand, Japan, India, Australia, and Europe. It started in West Virginia, and its headquarters is now located in Canonsburg, Pennsylvania.
Is Mylan Stock A Buy?
During the stock market crash, Mylan dropped from a 52-week high in February of $23.11 to a 52-week low of $12.75. It never again reached $20 per share for the remainder of 2020 and struggled to stay above $15 per share. This gives is a market capitalization of between $8 billion and $9 billion for the back half of the year.
Risks Of Buying Mylan Stock
Mylan was an early leader in the coronavirus vaccine race. Researchers assumed its malaria and HIV medications could also be used for treatment of this virus.
Mylan Vs Competitors
Mylan already lost the COVID-19 vaccine race to its competitors. It’s not out of the question that it faces stiffer competition from these better-funded companies which received government assistance.
Is Mylan Stock a Buy? The Bottom Line
Mylan is a massive global pharmaceutical giant that was at the frontlines of the coronavirus pandemic. Unfortunately, its proposed treatments failed to show efficacy, and it lose luster while its competitors outshined it in both headlines and the market. This pushed the company to a low market cap during its merger with Pfizer’s Upjohn unit.
About Mylan
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally.
Headlines
Viatris Vs. Organon: Surprisingly Undervalued, But Which Is The Better Buy? - Seeking Alpha
